Therefore, we and other studies established that the BTLA/HVEM pathway on both circulating T cells and tumor-infiltrating T cells plays a key role in tumor immunosuppression and serves as potential targets for cancer immunotherapy [14, 25, 31, 37, 39, 42, 43]. This evidence concerns the gene BTLA and cancer.